Atrium; Fibrillation Clinical Trial
Official title:
Efficacy and Safety of Refralon in Patients With Recurrent Atrial Fibrillation and Atrial Flutter After Catheter Ablation.
It is planned to evaluate the efficacy and safety of the class III antiarrhythmic drug refralon as a drug for pharmacological cardioversion in patients with recurrent atrial fibrillation (AF) and atrial flutter (AFL) after catheter ablation.
Atrial fibrillation and atrial flutter are the most common arrhythmias among the adult population of the world, their share in the population is from 2 to 4% and continues to grow. Modern highly effective methods of minimally invasive surgical treatment of these types of arrhythmia are currently catheter radiofrequency ablation and balloon cryoablation of the pulmonary veins. According to the CABANA study, catheter interventions reduce the risk of recurrent AF/AFL by 47%, significantly improving arrhythmia tolerance and improving the quality of life of patients. An important problem is the recurrence of arrhythmia after the intervention, the frequency of recurrence of AF/AFL in the first 3 months after ablation (the so-called early recurrence) is 50-60%. In many patients, these recurrence are accompanied by severe clinical manifestations, which require pharmacological or electrical cardioversion. In order to restore sinus rhythm, electrical cardioversion is most often used, the effectiveness of which is 90-92%. An alternative to electrical cardioversion is pharmacological cardioversion, however, antiarrhythmic drugs used in wide clinical practice can restore sinus rhytm (SR) only in patients with recent AF paroxysms. In 2014, a new Russian class III antiarrhythmic drug, Refralon, was registered. The effectiveness of the Refralon as a means of cardioversion in patients with persistent AF/AFL is 90%, in patients with paroxysmal AF/AFL - 95%. At present, there is no information on the efficacy and safety of the use of refralon in patients with AF / AFL who underwent catheter ablation. The growing number of catheter ablation in the world dictates the to study new approaches to performing cardioversion in this cohort of patients. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05434650 -
Abbott Atrial Fibrillation Post Approval Study
|
||
| Completed |
NCT02949180 -
Enhanced Diagnostics for Early Detection of Atrial Fibrillation - Prospective Validation
|
N/A | |
| Recruiting |
NCT05633303 -
Personalised Ablation Strategies in AF
|
N/A | |
| Completed |
NCT04293198 -
Evaluating the Performance of the KODEX-EPD CRyOballoon Occlusion Feature in Patients With Atrial Fibrillation
|
||
| Not yet recruiting |
NCT05973474 -
The Atherogenic Index of Plasma（AIP） in Patients With Atrial Fibrillation
|
||
| Not yet recruiting |
NCT06402851 -
Vitamin K AntagonISt, Factor Xa Inhibitor Or Nothing In Atrial Fibrillation And DIalytic End-stage Renal DiseasE (VISIONAIRE)
|
Phase 4 | |
| Not yet recruiting |
NCT06165510 -
Convergent Ablation Plus Left Atrial Appendage Isolation for the Treatment of Persistent Atrial Fibrillation
|
N/A | |
| Completed |
NCT03477734 -
Performance and Efficacy of the CardiacSense1 for Detection of Atrial Fibrillation
|
N/A | |
| Recruiting |
NCT04545437 -
The Short and Long-term Cardiovascular Consequences of Critical Illness: The C3 Study
|
||
| Recruiting |
NCT03487419 -
Echocardiographic Left Atrial Function Assessment and Atrial Fibrillation Post-Coronary Artery Bypass Surgery
|